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PURPOSE. The purpose of this study was to determine associations between macular drusen
parameters derived from an automatic optical coherence tomography (OCT) algorithm,
nonadvanced age-related macular degeneration (AMD) stage, and genetic variants.
METHODS. Eyes classified as early or intermediate AMD with OCT imaging and genetic data
were selected (n ¼ 239 eyes). Drusen area and volume measurements were estimated using
the Zeiss Cirrus advanced retinal pigment epithelium analysis algorithm in a perifoveal zone
centered on the fovea. Associations between drusen measurements and common genetic
variants in the complement and high-density lipoprotein (HDL) lipid pathways and the
ARMS2/HTRA1 variant were calculated using generalized estimating equations and linear
mixed models adjusting for age, sex, smoking, body mass index, and education.
RESULTS. Drusen area ‡ the median was independently associated with a higher number of
risk alleles for CFH risk score and risk variants in C3 and ARMS2/HTRA1 compared with eyes
with no measurable drusen. Similar results were obtained for drusen volume. When all genes
were analyzed in the same model, only CFH score and ARMS2/HTRA1 were associated with
drusen measurements. HDL pathway genes were not significantly related to drusen
parameters. Nonadvanced AMD stages were associated with OCT-derived drusen area and
volume.
CONCLUSIONS. Variants in CFH and ARMS2/HTRA1, commonly associated with advanced AMD,
were independently associated with an increase in drusen burden determined by OCT in an
allele dose dependent manner, in eyes with early and intermediate AMD. Biomarkers such as a
quantitative classification of nonadvanced AMD and other OCT-derived subphenotypes could
provide earlier anatomic endpoints for clinical trials and facilitate the development of new
therapies for AMD.
Keywords: age-related macular degeneration, drusen, genetic diseases
Age-related macular degeneration (AMD) is a leading cause ofvision loss and irreversible blindness in adults older than
age 60.1 The etiology of AMD is multifactorial, and both
behavioral and genetic risk factors contribute to personal
risk.2,3 The genetic component of AMD risk is particularly well
documented with regard to progression to advanced disease,
including transitions to both advanced subtypes: geographic
atrophy (GA) and neovascular disease (NV).4–7 Each advanced
subtype is generally preceded by early and intermediate stages
of disease that are primarily characterized by the formation of
drusen between the retinal pigment epithelium (RPE) and
Bruch’s membrane. The mechanisms by which an individual
might develop GA or NV are not fully understood; however, it is
clear that drusen development is predictive of progression to
both forms of advanced disease.8,9 Management of the growing
burden of advanced AMD remains a significant challenge.
Therefore, identification of therapeutic targets for earlier, high-
risk stages of the disease is needed to lower the rate of
progression to advanced stages and to preserve vision.
With advances involving in vivo imaging, spectral domain–
optical coherence tomography (SD-OCT) devices are capable
of noninvasive visualization and discrimination of the retinal
and choroidal layers. Dysfunction of the RPE, including area
and volume abnormalities at locations where drusen develop,
can be directly visualized and measured using OCT. Prior
studies have indicated that OCT-derived drusen area and
volume and retinal features such as hyper-reflective foci and
choroidal parameters are informative in determining the
likelihood of progression from early or intermediate to
advanced AMD.10–15
However, knowledge about the association between OCT
derived retina parameters and genetic variants related to AMD
is sparse.16–18 We previously reported the effects of genes on
progression to different stages of AMD.19 In that study, genes in
the complement pathway were associated with a higher risk of
progression from small and intermediate to large size drusen
and from large size drusen to GA and NV. A novel association
was also found between the ABCA1 gene in the HDL pathway
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that reduced the risk of progression from normal to
intermediate drusen and from intermediate to large drusen.
Protective effects for transitions to advanced disease and larger
drusen size were also observed in other pathways.20,21 These
assessments provide a framework to evaluate the role of
genetics as they relate to drusen measurements based on OCT.
We evaluated the association between genetic risk and OCT
derived drusen area and volume in a clinical cohort of patients
with early and intermediate AMD. Understanding these
relationships, in addition to other OCT parameters,10–15,22
may lead to clinical use of these measurements with
identification of earlier high-risk phenotypes and better
stratification of risk of progression. Further characterization
of drusen morphology on OCT may lead to the identification of
disease biomarkers that could serve as anatomic end points for
clinical trials. Our study aimed to evaluate the associations
between a subset of genes implicated in risk of advanced AMD,
and drusen area and volume measurements based on OCT in
eyes with clinically diagnosed early and intermediate AMD.
Preliminary results were presented at AAO in 201723 and at
ARVO in 2019 (Widjajahakim et al. IOVS 2019;60:ARVO E-
Abstract 1164).
METHODS
Study Population and Classification of AMD
Phenotypes
All participants were previously enrolled in our ongoing genetic
and epidemiologic studies of AMD beginning in 1985.24–27
Participants were derived from clinic populations and nation-
wide referrals and were prospectively followed. The study
protocol includes an ocular examination, fundus photography,
and OCT imaging, as well as interviews and blood sampling.
This research adhered to the tenets of the Declaration of
Helsinki and was approved by the institutional review board.
Written informed consent was obtained for all participants.
AMD phenotypes were based on ocular examination and
ocular imaging. Eyes were classified using the Clinical Age-
Related Maculopathy Staging (CARMS) system by JMS as
previously described.28 CARMS grades were defined as follows:
grade 1 (no AMD, no drusen or only a few small drusen <63
lm); grade 2 (early AMD, RPE irregularities and/or intermedi-
ate size drusen 63–124 lm); grade 3 (intermediate AMD, large
drusen ‡125 lm); grade 4 (advanced dry AMD, or GA,
including both central and noncentral GA); and grade 5
(advanced exudative AMD with choroidal neovascularization).
Risk factors were determined using our standardized
questionnaire including demographic information (age, sex,
education), anthropomorphic data (height and weight con-
verted to body mass index [BMI]), and smoking.2,29–31
Evaluation of Drusen Area and Volume
Measurements
Beginning in 2007, OCT scans were included in our study
protocols for the purpose of conducting studies to assess OCT
parameters associated with various stages of AMD, AMD
progression, and genetic factors. In 2016, a retrospective
review of Cirrus SD-OCT 4000 and 5000 scans (Carl Zeiss
Meditec, Inc., Dublin, CA, USA) was conducted among
individuals with one or both eyes with stage 2 or 3. The
OCT scanning protocols included high-definition 1-line scan, 5-
line scan, and macular cube (5123 128:128 B-scans and 512 A-
scans per B scan) over a 6- 3 6-mm square, centered on the
fovea.32 The position of the fovea was determined by the OCT
technician to match the known anatomic configuration of the
fovea. Drusen area and volume measurements were deter-
mined by the Cirrus Version 6.0 Advanced RPE Analysis
algorithm, a fully automated algorithm available using the
Cirrus SD-OCT instrument. This algorithm is based on an
automatic determination of the RPE floor and measurement of
the elevations of the RPE deformations. This yields an
automatic quantitative assessment of RPE deformations and
calculates measurements of area and volume that are highly
reproducible.33–35 These measurements provide an estimate of
drusen burden for a circle with 5 mm in diameter (perifoveal
zone) centered on the fovea.32
Only eyes with early or intermediate AMD (CARMS grades 2
or 3) at the time of the OCT scan were selected for inclusion in
the analyses. We selected participants with at least one OCT
macular cube scan in at least one eye and with DNA
genotyping data. Scans with signal strength less than 6 of 10
were excluded, similar to what has been previously report-
ed.14,36 For individuals with multiple scans, the earliest,
highest-quality scan was evaluated.
Genotyping and Genetic Data
Enrolled participants provided blood or saliva samples for DNA
extraction according to a standard study protocol. Genotypes
were determined using array-based and gene sequencing
platforms as previously described.24,25,37,38 All single nucleotide
polymorphisms (SNPs) had a high genotype call rate (>98%),
and PLINK was used to perform all quality control steps.39
Common variants in genes previously associated with
drusen and AMD in the complement pathway, HDL pathway,
and the gene locus on chromosome 10q26 were selected given
their consistent association with advanced disease or biolog-
ically plausible relationship to drusen formation. The genetic
variants included complement factor H (CFH) Y402H
rs1061170,40 CFH rs1410996,37,41 age-related maculopathy
susceptibility 2/high-temperature requirement A serine pepti-
dase 1 locus on chromosome 10q26 (ARMS2 A69S/HTRA1)
represented by SNP rs10490924,42,43 complement component
3 (C3) R102G rs2230199,44 and variants in the HDL pathway:
hepatic lipase C (LIPC) rs10468017,45 adenosine tri-phosphate
binding cassette transporter 1 (ABCA1) rs1883025,and choles-
teryl ester transfer protein (CETP) rs3764261.19,20,45,46
Statistical Methods
A total of 239 eyes among 179 participants were included in
these analyses. The distributions of demographic (age [<70,
70–79, ‡80], sex, education [high school, >high school]),
behavioral (smoking and BMI), ocular (baseline AMD grade),
and genetic factors were evaluated for each area and volume
measurement. Categorical comparisons were made between
eyes with some drusen but <median versus eyes with no
measurable drusen, and eyes with some drusen but ‡median
versus eyes with no measurable drusen in separate models for
each outcome. Univariate associations between each genetic
factor and the drusen measurements were evaluated by
generalized linear models based on generalized estimating
equations (GEEs) using PROC GENMOD of SAS 9.4 with the
individual eye as the unit of analysis, using a logistic link and a
binomial distribution with a working independence correlation
structure to account for the correlation between fellow
eyes.47,48 We only considered eyes without advanced AMD
because drusen morphology is altered by the presence of
advanced AMD; thus, some subjects contributed two eyes to
the analyses, whereas other subjects contributed a single eye if,
for example, the fellow eyes had advanced AMD. In addition, a
multivariate model included all genetic factors in the same
model. All models were adjusted for age, sex, smoking, BMI,
OCT-Derived Drusen Burden and Genetic Risk in Nonadvanced AMD IOVS j October 2019 j Vol. 60 j No. 13 j 4470
Downloaded from iovs.arvojournals.org on 11/13/2019
and education. Two distinct outcomes of interest were
assessed: drusen area and drusen volume in the perifoveal
zone. Genetic variables were defined as having zero, one, or
two risk or protective alleles. For the two CFH variants that
convey different information about AMD risk (R2 ¼ 0.44), we
combined them into a risk score category from zero to four,
consisting of the total number of alleles in the two variants
combined. Odds ratios (ORs) and 95% confidence intervals
(CIs) were calculated per allele as estimates of effect size.
Because we identified consistent significant associations in
categorical analyses between drusen measurements and risk
genotypes for CFH risk score and ARMS2/HTRA1, we looked
in more detail at mean area and volume represented as
continuous variables for these two genes and assessed the
independent effects of each gene on drusen measurements.
For these analyses, AMD grade was included as an additional
covariate. Associations between continuous drusen measure-
ments and AMD stages and genotypes were evaluated by a
linear mixed effects model using PROC MIXED of SAS 9.4 with
the individual eye as the unit of analysis. This accounts for the
intereye correlation in drusen area and volume between fellow
eyes.48 The LSMEANS option of PROC MIXED was used to
compute adjusted means of area and volume measurements for
specific genotype categories and AMD grades. In addition, we
used the LSMEANS option to compute adjusted means for area
and volume for categories of the CFH risk score, adjusted for
age, sex, smoking, BMI, education, AMD grade, and ARMS2/
HTRA1 genotype (and similarly, LSMEANS for categories of the
ARMS2/HTRA1 genotype were adjusted for CFH risk score).
We tested for significant interactions between CFH and
ARMS2/HTRA1, by first creating binary variables for each gene
(CFH risk score: three or four alleles with reference¼ 0–2; and
ARMS2/HTRA1 GT and TT as one or two risk alleles with
reference¼GG as 0), and then creating the cross-product of the
two binary variables. Finally, we estimated Pearson correlation
between area and volume measurements.49 Two-sided P < 0.05
was considered statistically significant. All analyses were
conducted using SAS 9.4 (SAS Institute, Cary, NC, USA).
RESULTS
Distributions of area and volume for different drusen categories
are shown in Supplementary Table S1. More than 50% of the
analyzed eyes had measurable drusen, with a wide range in
both area and volume among these eyes. The Pearson
correlation between area and volume for individual eyes was
0.84, indicating similarity between the two measurements.
Relationships between age, sex, education, smoking, BMI, and
drusen parameters comparing no measurable drusen versus
<median drusen and no measurable drusen versus ‡median
drusen, were evaluated as shown in Supplementary Table S2.
Older age was associated with greater drusen area and volume,
and the other nongenetic factors were not significantly
associated with these drusen measurements.
Ocular Images of Drusen Measurements
Representative color fundus photographs and OCTs corre-
sponding to different measurements using the advanced RPE
analysis tool are shown in Figure 1 for no measurable drusen,
<median, and ‡median drusen measurements.
Association Between OCT Drusen Measurements
and AMD Grade
The mean OCT-derived drusen area was significantly associated
with grade of AMD based on color photographs and was higher in
intermediate AMD eyes than in early AMD eyes after adjusting for
age, sex, education, smoking, and BMI (P ¼ 0.008; Fig. 2A).
Similarly, the mean drusen volume was higher in eyes with
intermediate AMD compared with early AMD (P¼0.005; Fig. 2B).
Individual data points are shown in Supplementary Figure S1.
Associations Between Drusen Measurements and
Each AMD Genetic Variant
A higher CFH score was associated with greater drusen area in
the perifoveal 5-mm zone controlling for age, sex, education,
smoking, and BMI (Table 1). There was a significant association
between drusen area ‡median versus no measurable drusen
with OR ¼ 1.79 (95% CI, 1.18–2.71; P¼ 0.01) per category of
CFH score. Therefore, the OR is 5.74 (equal to 1.793) for
category 3þ vs. 0. For the variant in another complement
pathway gene, C3 R102G, there was a significant association
between drusen area ‡median versus no measurable drusen
with OR ¼ 1.80 (95% CI, 1.07–3.03; P ¼ 0.03) per risk allele
(G). A higher number of risk alleles for the variant in ARMS2/
HTRA1 was also associated with greater drusen area control-
ling for age, sex, education, smoking, and BMI. For the variant
at this locus, there was a significant association between
drusen area ‡median versus no measurable drusen with OR¼
2.76 (95% CI, 1.57–4.86; P < 0.001) per each risk allele (T).
Genetic variants in the HDL pathway were not significantly
associated with drusen area.
Results for each genetic factor analyzed separately for
association with the other drusen parameter, drusen volume,
are shown in Table 2. Higher CFH score was associated with
‡median drusen volume compared with no measurable drusen
volume (OR¼ 1.73; 95% CI, 1.13–2.64; P¼ 0.01) per category of
CFH score. C3 R102G was also related to drusen volume, with a
significant association between number of risk alleles and drusen
volume ‡median compared with no drusen volume with OR ¼
1.92 (95% CI, 1.09–3.41; P¼0.03) per risk allele. ARMS2/HTRA1
FIGURE 1. Representative color fundus photographs and OCTs
corresponding to different measurements using the advanced RPE
analysis tool are shown as (A) no measurable drusen, (B) drusen area
and volume <median, and (C) drusen area and volume ‡median.
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FIGURE 2. Associations between OCT-derived drusen measurements and early and intermediate stages of AMD for (A) drusen area (P¼ 0.008) and
(B) drusen volume (P¼0.005). The diamond represents the adjusted mean controlling for age, sex, education, smoking, and BMI. The vertical line
represents 6SE of the adjusted mean.
TABLE 1. Associations Between Drusen Area Measurements and Individual Genetic Loci*
Gene/Variant
No Drusen Measured
(N ¼ 111)
Drusen Area < Median (N ¼ 54) Drusen Area ‡ Median (N ¼ 74)
OR (95% CI)† P Value‡ OR (95% CI)† P Value‡
CFH score 1.0 (ref) 0.97 (0.65–1.47) 0.90 1.79 (1.18–2.71) 0.01
ARMS2/HTRA1: rs10490924 1.0 (ref) 1.29 (0.77–2.14) 0.33 2.76 (1.57–4.86) <0.001
C3 R102G: rs2230199 1.0 (ref) 0.99 (0.57–1.72) 0.98 1.80 (1.07–3.03) 0.03
ABCA1: rs1883025 1.0 (ref) 0.66 (0.32–1.37) 0.26 0.67 (0.35–1.31) 0.24
LIPC: rs10468017 1.0 (ref) 1.14 (0.61–2.12) 0.68 0.87 (0.51–1.50) 0.62
CETP: rs3764261 1.0 (ref) 1.15 (0.67–1.98) 0.62 1.49 (0.92–2.40) 0.10
* Each genetic variant assessed in a model, controlling for age, sex, education, body mass index, and smoking.
† OR and CI per risk or protective allele. CFH score categorized as 0, 1, 2, 3–4 risk score categories.
‡ Based on GEE using PROC GENMOD of SAS with the eye as the unit of the analysis using a logistic link and a binomial distribution with the
working independence model to account for the intereye correlation. Separate analyses were performed (1) comparing eyes with measurable
drusen less than the median versus eyes with no drusen and (2) comparing eyes with measurable drusen greater than or equal to the median versus
eyes with no drusen. The reference category is no drusen measured.
TABLE 2. Associations Between Drusen Volume Measurements and Individual Genetic Loci*
Gene/Variant
No Drusen Measured
(N ¼ 96)
Drusen Volume < Median (N ¼ 66) Drusen Volume ‡ Median (N ¼ 77)
OR (95% CI)† P Value‡ OR (95% CI)† P Value‡
CFH score 1.0 (ref) 0.99 (0.66–1.48) 0.96 1.73 (1.13–2.64) 0.01
ARMS2/HTRA1: rs10490924 1.0 (ref) 1.29 (0.77–2.16) 0.34 2.72 (1.48–5.01) <0.001
C3 R102G: rs2230199 1.0 (ref) 0.99 (0.55–1.79) 0.98 1.92 (1.09–3.41) 0.03
ABCA1: rs1883025 1.0 (ref) 0.69 (0.36–1.34) 0.28 0.62 (0.32–1.22) 0.17
LIPC: rs10468017 1.0 (ref) 0.94 (0.53–1.66) 0.82 0.88 (0.50–1.53) 0.65
CETP: rs3764261 1.0 (ref) 1.17 (0.69–1.99) 0.56 1.63 (0.99–2.68) 0.06
* Each genetic variant assessed in a model, controlling for age, sex, education, body mass index, and smoking.
† OR and CI per risk or protective allele. CFH score categorized as 0, 1, 2, 3–4 risk score categories.
‡ Based on GEE using PROC GENMOD of SAS with the eye as the unit of the analysis using a logistic link and a binomial distribution with the
working independence model to account for the intereye correlation. Separate analyses were performed (1) comparing eyes with measurable
drusen less than the median versus eyes with no drusen and (2) comparing eyes with measurable drusen greater than or equal to the median versus
eyes with no drusen. The reference category is no drusen measured.
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risk was associated with greater drusen volume compared with
no drusen volume (OR ¼ 2.72; 95% CI, 1.48–5.01; P < 0.001).
The variant in the HDL gene, CETP, was borderline associated
with higher drusen volume compared with no drusen volume
with OR¼ 1.63 (95% CI, 0.99–2.68; P¼ 0.06).
Multivariate Analyses of Associations Between
Drusen and Genetic Variants
When analyzing each genetic variable while controlling for all
of the other variants, only two genetic variables, CFH risk score
and the ARMS2/HTRA1 variant, remained independently
associated with a significantly higher drusen area (‡median
compared with no measurable drusen) as shown in Table 3.
For CFH score, the OR was 1.58 (95% CI, 1.01–2.46; P¼ 0.04),
and for the ARMS2/HTRA1 variant, the OR was 2.45 (95% CI,
1.35–4.45; P < 0.001).
Multivariate associations between genes and drusen volume
controlling for all genes are shown in Table 4. Comparing
drusen volume ‡median to no measurable drusen, CFH score
had an OR of 1.54 (95% CI, 0.97–2.45; P ¼ 0.07). ARMS2/
HTRA1 remained significant with an OR¼ 2.49 (95% CI, 1.29–
4.80; P¼ 0.01). The C3 and CETP variants were not associated
with higher drusen volume (P ¼ 0.09).
Independent Associations Between Drusen
Measurements and CFH Score and ARMS2/HTRA1
As shown in Table 5, both mean perifoveal drusen area and
volume increased as the CFH score increased, and the trends
for increasing drusen burden as the CFH score increased were
significant after adjusting for age, sex, education, smoking,
BMI, and AMD grades (P trend ¼ 0.004 for area and P trend ¼
0.002 for volume). Carriers of two risk alleles versus zero or
one had higher drusen area (P¼ 0.03) and drusen volume (P¼
0.04), and carriers of three or four risk alleles also had
significantly higher drusen area (P < 0.001) and volume (P <
0.001) compared with having zero or one risk alleles. Similar
comparisons were assessed for the ARMS2/HTRA1 variant:
mean drusen area and volume increased as the number of risk
alleles increased, after adjustment for other variables (P trend
< 0.001 for both drusen area and volume). Carrying two risk
alleles versus none was significantly related to higher drusen
area and volume (P ¼ 0.008 and 0.004, respectively). These
associations between OCT-derived perifoveal drusen measure-
ments and genetic factors are also depicted in Figure 3.
When both genes were adjusted for each other (bivariate
analyses shown in Table 5), the associations between drusen
measurements and CFH score were somewhat reduced.
However, the trend for higher drusen area and volume with
higher score remained significant (P trend ¼ 0.01 for area; P
trend ¼ 0.005 for volume). When the ARMS2/HTRA1 genetic
variant was adjusted for the CFH score, results were essentially
unchanged from the univariate analysis as above, and trends for
increasing drusen area and volume with increasing number of
ARMS2/HTRA1 risk alleles were significant (P trend < 0.001
and 0.001 for area and volume, respectively).
All tests of interaction between CFH score and ARMS2/
HTRA1 were not significant. When comparing drusen area or
volume measurements ‡median versus no measurable drusen,
TABLE 3. Multivariate Analyses of Associations Between Drusen Area and Genetic Loci*
Gene/Variant
No Drusen Measured
(N ¼ 111)
Drusen Area < Median (N ¼ 54) Drusen Area ‡ Median (N ¼ 74)
OR (95% CI)† P Value‡ OR (95% CI)† P Value‡
CFH score 1.0 (ref) 0.93 (0.61–1.41) 0.73 1.58 (1.01–2.46) 0.04
ARMS2/HTRA1: rs10490924 1.0 (ref) 1.24 (0.72–2.15) 0.44 2.45 (1.35–4.45) <0.001
C3 R102G: rs2230199 1.0 (ref) 1.00 (0.55–1.82) 0.99 1.57 (0.87–2.85) 0.14
ABCA1: rs1883025 1.0 (ref) 0.65 (0.31–1.38) 0.27 0.84 (0.41–1.73) 0.65
LIPC: rs10468017 1.0 (ref) 1.14 (0.61–2.12) 0.69 0.76 (0.43–1.36) 0.36
CETP: rs3764261 1.0 (ref) 1.17 (0.67–2.04) 0.57 1.28 (0.78–2.12) 0.33
* Each genetic variant assessed in a model, controlling for age, sex, education, body mass index, and smoking.
† OR and CI per risk or protective allele. CFH score categorized as 0, 1, 2, 3–4 risk score categories.
‡ Based on GEE using PROC GENMOD of SAS with the eye as the unit of the analysis using a logistic link and a binomial distribution with the
working independence model to account for the intereye correlation. Separate analyses were performed (1) comparing eyes with measurable
drusen less than the median versus eyes with no drusen and (2) comparing eyes with measurable drusen greater than or equal to the median versus
eyes with no drusen. The reference category is no drusen measured.
TABLE 4. Multivariate Analyses of Associations Between Drusen Volume and Genetic Loci*
Gene/Variant
No Drusen Measured
(N ¼ 96)
Drusen Volume < Median (N ¼ 66) Drusen Volume ‡ Median (N ¼ 77)
OR (95% CI)† P Value‡ OR (95% CI)† P Value‡
CFH score 1.0 (ref) 0.95 (0.64–1.42) 0.81 1.54 (0.97–2.45) 0.07
ARMS2/HTRA1: rs10490924 1.0 (ref) 1.27 (0.74–2.18) 0.39 2.49 (1.29–4.80) 0.01
C3 R102G: rs2230199 1.0 (ref) 1.00 (0.53–1.90) 1.00 1.78 (0.92–3.45) 0.09
ABCA1: rs1883025 1.0 (ref) 0.69 (0.36–1.35) 0.28 0.76 (0.37–1.57) 0.45
LIPC: rs10468017 1.0 (ref) 0.91 (0.51–1.62) 0.75 0.73 (0.41–1.32) 0.30
CETP: rs3764261 1.0 (ref) 1.19 (0.69–2.04) 0.53 1.54 (0.93–2.54) 0.09
* Each genetic variant assessed in a model, controlling for age, sex, education, body mass index, and smoking.
† OR and CI per risk or protective allele. CFH score categorized as 0, 1, 2, 3–4 risk score categories.
‡ Based on GEE using PROC GENMOD of SAS with the eye as the unit of the analysis using a logistic link and a binomial distribution with the
working independence model to account for the intereye correlation. Separate analyses were performed (1) comparing eyes with measurable
drusen less than the median versus eyes with no drusen and (2) comparing eyes with measurable drusen greater than or equal to the median versus
eyes with no drusen. The reference category is no drusen measured.
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the P values were 0.38 for drusen area and 0.33 for drusen
volume (data not shown).
DISCUSSION
We evaluated associations between measurements of perifo-
veal drusen area and volume and common risk and protective
alleles known to be related to advanced AMD in patients with
early and intermediate AMD. Drusen area and volume
measurements were estimated using the advanced RPE analysis
algorithm from Zeiss Cirrus OCT. These measurements were
related to stage of nonadvanced AMD and were greater for eyes
classified as having intermediate AMD compared with early
AMD. In addition, among eyes with the same AMD grade (early
or intermediate), genetic risk was associated with a higher
drusen burden. CFH score and ARMS2/HTRA1 were indepen-
dently associated with perifoveal drusen area and volume
compared with no measurable drusen.
Interestingly, genes in the HDL pathway were not signifi-
cantly associated with drusen area and volume. Significant
associations between drusen parameters and the C3 variant
were seen in univariate analyses but not in the multivariate
analyses.
When comparing the adjusted means of the drusen area and
volume for CFH score and ARMS2/HTRA1, we found
significant trends for increasing drusen measurements with
increasing number of risk alleles for each variant. The trends
persisted when both genes were adjusted for each other, as
well as when the baseline AMD grade was included as a
covariate in the analysis. There was no interaction between
these genetic factors when assessing their association with
drusen parameters. These two genetic variants contributed
independently to drusen burden.
Prior studies investigating the role of genetics and drusen
assessments based on OCT are limited and inconsistent.
Chavali et al.17 studied an Amish population with early AMD
and found an association between drusen and risk alleles in
CFH rs12038333 and SYN3 rs5749482, but not ARMS2.
Authors reported that the population had a high rate of
homozygous risk allele of SYN3 and suggested that this
population has a unique genetic background. Oeverhaus et
al.50 evaluated 85 patients in Germany for only CFH and
ARMS2 and individuals homozygous for each genetic variant
had larger amounts of drusen and different types of drusen
based on manual OCT measurements, although multivariate
analyses and measurements of area and volume of drusen
based on an automatic OCT algorithm were not assessed. A
study of change in drusen volume over 1 year among 30
patients in Florida who participated in a study of eculizamab
showed an association with CFH rs1061170 but not ARMS2/
HTRA1.18 Drusen volume based on OCT was assessed in the
Singapore Eye Disease program, and only ARMS2 was
associated with drusen volume, although the CFH SNPs in
our risk score and drusen area were not evaluated.51
The value in obtaining and following these OCT drusen
measurements over time has been suggested. Folgar et al.13
showed that greater baseline OCT drusen volume was
associated with increased risk of progression to NV over 2
years. Sleiman et al.52 demonstrated that OCT based drusen
measurements were associated with appearance of geographic
atrophy on color photographs over 4 years. Schmidt-Erfurth et
al.15 found that drusen area was an important quantitative
feature for progression. Higher drusen volume was related to
advanced AMD in a retrospective review by Lei et al.,22 but
other OCT parameters were more strongly related in their
cases. A combination of drusen parameters along with other
OCT-derived parameters such as hyper-reflective foci and
retinal thickness may be the most informative and predictive
of progression.14,15,22
The association between advanced AMD and the CFH
Y402H variant, as well as the intronic SNP in this gene, CFH
rs1410996, has been well documented.5,19,37,41,53–55 The
biologic mechanisms underlying their effect on drusen
accumulation, however, have not been fully explored. In our
previous analyses of these variants regarding progression, the
effect of rs1410996 was stronger and the effect of Y402H was
reduced when both were in the same model, suggesting that
this variant may be more strongly associated with AMD.4–6,55
CFH negatively regulates the alternate complement pathway
TABLE 5. Associations Between Drusen Area and Volume and CFH and ARMS2/HTRA1
No. of Risk
Alleles
Univariate Gene Analysis* Bivariate Gene Analysis†
n (Eyes)
Drusen Area
Mean
(mm2 6 SE) P Value
Drusen Volume
Mean
(mm3 6 SE) P Value
Drusen Area
Mean
(mm2 6 SE) P Value
Drusen Volume
Mean
(mm3 6 SE) P Value
CFH Risk Score‡
0-1 39 0.07 6 0.16 Ref 0.0002 6 0.008 Ref 0.25 6 0.17 Ref 0.007 6 0.008 Ref
2 103 0.49 6 0.10 0.03 0.019 6 0.005 0.04 0.57 6 0.11 0.09 0.022 6 0.005 0.11
3–4 97 0.66 6 0.10 <0.001 0.029 6 0.005 <0.001 0.74 6 0.11 0.01 0.032 6 0.005 0.006
P (trend) 0.004 0.002 0.01§ 0.005§
ARMS2/HTRA1: rs10490924j j
0 105 0.19 6 0.10 Ref 0.007 6 0.005 Ref 0.15 6 0.098 Ref 0.005 6 0.0047 Ref
1 104 0.68 6 0.10 <0.001 0.028 6 0.005 0.002 0.60 6 0.10 0.001 0.024 6 0.005 0.004
2 30 0.90 6 0.19 0.008 0.036 6 0.009 0.004 0.80 6 0.19 0.002 0.031 6 0.0089 0.009
P (trend) <0.001 <0.001 <0.001j j 0.001j j
* Analyses based on continuous area and volume, adjusting for age, sex, education, body mass index, smoking, and AMD grade using the
LSMEANS option of PROC MIXED of SAS. Each genetic factor was analyzed separately.
† Analyses for CFH score are based on continuous area and volume, adjusting for age, sex, education, body mass index, smoking, AMD grade, and
number of ARMS2/HTRA1 risk alleles using the LSMEANS option of PROC MIXED of SAS. Analysis for ARMS2/HTRA1 was performed similarly,
adjusting for CFH score.
‡ No. of risk alleles for rs1410996 and rs1061170 combined.
§ The P trend assessing effect on drusen measurements per one category increase in CFH score was obtained after adjusting for number of
ARMS2/HTRA1 risk alleles and other risk factors.
j j The P trend assessing effect of increase in ARMS2/HTRA1 risk alleles was obtained after adjusting for categories of the CFH score and other
risk factors.
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FIGURE 3. Independent associations between OCT-derived perifoveal drusen measurements and number of risk alleles for drusen area for (A) CFH
score and (B) ARMS2/HTRA1 rs10490924 (P trend¼0.004 and <0.001, respectively) and drusen volume for (C) CFH score and (D) ARMS2/HTRA1
rs10490924 (P trend¼ 0.002 and <0.001, respectively). The diamond represents the adjusted mean controlling for age, sex, education, smoking,
BMI, and AMD grade. The vertical line represents 6SE of the adjusted mean.
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and dampens the excessive C3 convertase activated by either
immune complex deposition or C3 convertase activation from
pathogens or damaged cell surfaces. CFH risk variants are
functionally less efficient at dampening down this response,
leading to heightened complement activity, which can lead to
AMD-related pathology.
It should be noted that SNPs in the genes ARMS2 and
HTRA1 at the chromosome 10q26 locus are in very high
linkage disequilibrium, and functional studies are needed to
determine which gene products lead to AMD pathology.43 The
function of the ARMS2 protein in humans and the conse-
quences of the A69S variant have been explored but have not
been confirmed. One study found that ARMS2 was expressed
in human monocytes and microglia cells and facilitated
removal of cellular debris by local complement activation;
the A69S variant resulted in ARMS2 deficiency, possibly
impairing the removal of cellular debris at Bruch’s membrane,
leading to the development of drusen.56 On the other hand,
another study reported that ARMS2 mRNA and protein are
expressed at extremely low levels in eye tissues and presented
support for HTRA1 as the risk factor for AMD.57
We found that the OCT algorithm yielded drusen measure-
ments that were highly associated with the manual CARMS
grading. This advanced RPE analysis algorithm or a similar
method may be useful for ophthalmologists or reading centers
to categorize the stage of AMD more efficiently, with higher
precision and with the ability to quantify the measurements,
compared with clinical observation or photography. Higher-
resolution OCT may reduce variability in OCT grading and
enhance the application of the RPE analysis algorithm. Future
studies will continue to provide more information about the
impact of genetic variants on drusen morphology.
Strengths
Strengths of this study include the assessment of plausible
genetic pathways, the inclusion of high-quality scans, and use
of a commercially available means of estimating drusen
measurements that is incorporated into Cirrus SD-OCT
instruments. Automated RPE analysis has been shown to be
consistent and reproducible, especially between repeated
scans.35,58 We also conducted eye-specific analyses adjusting
for correlation between eyes, analyzed both drusen area and
volume, and controlled for demographic and behavioral risk
factors associated with AMD.
Limitations
Some of the AMD-associated genes did not show an association
with drusen area or volume in eyes with early and intermediate
AMD. This may be due to lack of an association or insufficient
power secondary to a limited number of eyes in the
homozygous risk or protective genotype category in some of
these genes. We did not find a significant association between
OCT-derived drusen measurement and the HDL pathway genes
(ABCA1, LIPC, and CETP), although effect estimates were in
the direction previously seen in a prospective analysis.19 Of
note, the same genes (CFH and ARMS2/HTRA1) significantly
related to the transition from early to intermediate AMD in Yu
et al.19 based on color photographs were also associated with
larger OCT-derived drusen measurements in our analyses as
seen in Tables 1 to 5 of the current paper.
We observed that some small drusen seen on color
photographs were classified as having no measurable drusen
by the RPE algorithm on OCT. This may due to the basis of the
algorithm that has a threshold of 10-pixel elevation (19.5 lm)
before the measurements can be calculated.34 The developers
of the algorithm used this to prevent a false-positive RPE
elevation in the OCT due to noise. Drusen area and volume are
estimates assuming an eye with 24.46 mm in length so there
may be magnification differences between eyes. Furthermore,
drusen outside the perifoveal zone were not measured because
they were located outside the scanned or analyzed zone.59
Because the same algorithm for measuring drusen parameters
was applied to all data uniformly, the relative rankings of the
area and volume measurements were internally valid.
CONCLUSIONS
In summary, this study determined that risk alleles in AMD-
associated genes, CFH and ARMS2/HTRA1, were independent-
ly associated with greater drusen area and volume based on
automated measurements of RPE using the Zeiss SD-OCT
algorithm. The associations between these genes and drusen
remained significant after controlling for all other genes, as
well as the nongenetic covariates. The C3 variant was
associated with drusen area and volume only in univariate
analyses. Results confirm some findings in the few previous
studies in different populations but also contribute new
information and analyses to support the involvement of both
CFH and ARMS2/HTRA1 genes in drusen development.
As our understanding of the genetic determinants of AMD
becomes clearer, it will be important to understand the specific
patho-biologic consequences of these genetic variants. SD-OCT
can quantify variation in morphology in a way that is accurate
and reproducible. Other AMD phenotypes detectable on OCT
including subfoveal fluid, retinal and choroidal thickness,
retinal hyper-reflective foci, and other drusen characteristics
such as hyper-reflectivity and homogeneity, are opportunities
for exploration in the context of subtyping AMD and assessing
risk of progression,14,15,22,52 as well as defining the associations
with genetic variants. Understanding the relationship between
disease severity, morphologic features, and genetic factors has
the potential to enhance individualized patient management
and treatment.
Genetic risk is associated with a higher drusen burden
assessed by OCT in eyes with early and intermediate stages of
AMD. Further characterization of drusen and retinal and
choroidal morphology may lead to the identification of
biomarkers that could serve as early anatomic end points for
clinical trials and facilitate the development of new therapies
for AMD.
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